ストックスクリーナーアプリを入手
72.36
2.11%
-1.56
前日終値:
$73.92
開ける：
$73.05
24時間の取引高:
2.73M
Relative Volume:
0.45
時価総額：
$28.24B
収益：
$4.30B
当期純損益:
$571.50M
株価収益率:
50.65
EPS:
1.4285
ネットキャッシュフロー:
$570.80M
1週間 パフォーマンス:
+4.06%
1か月 パフォーマンス:
+8.23%
6か月 パフォーマンス:
-16.28%
1年 パフォーマンス:
-17.49%
1日の値動き範囲:
$71.66
$73.53
1週間の範囲:
$68.54
$75.97
52週間の値動き範囲:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
DXCM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.41 | 28.83B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
106.40 | 188.86B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
91.73 | 135.38B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
351.38 | 137.16B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.83 | 129.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.59 | 49.00B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 開始されました | Evercore ISI | In-line |
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 開始されました | Argus | Buy |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
DexCom Inc (DXCM) Trading 4.47% Higher on Jan 22 - GuruFocus
Dexcom Reports 22% Revenue Growth to $1.2 Billion in 2024 Amidst Challenges - Intellectia AI
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
FDA Flags Serious Software Issue in Dexcom Glucose Monitoring App - Drugwatch.com
Analysts Are Bullish on Top Healthcare Stocks: Dexcom (DXCM), AbbVie (ABBV) - The Globe and Mail
DexCom Inc. (NASDAQ:DXCM) Combines Strong Fundamentals with Bullish Chart Pattern - Chartmill
Fisher Funds Management LTD Sells 91,159 Shares of DexCom, Inc. $DXCM - MarketBeat
Market Pulse: Can DexCom Inc be the next market leader2025 Technical Patterns & Detailed Earnings Play Strategies - baoquankhu1.vn
Dexcom (DXCM) releases preliminary, unaudited results for Q4 2025 - MSN
Is Dexcom the Next Sleeper Stock? The Real Talk on This Glucose Tech Giant - AD HOC NEWS
DexCom, Inc. $DXCM Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Pinnacle Financial Partners Inc Sells 33,980 Shares of DexCom, Inc. $DXCM - MarketBeat
Stephens Investment Management Group LLC Sells 16,732 Shares of DexCom, Inc. $DXCM - MarketBeat
Nordea Investment Management AB Boosts Stake in DexCom, Inc. $DXCM - MarketBeat
Is DexCom Stock Underperforming the S&P 500? - MSN
DexCom Stock Declines Following Strong Preliminary Q4 Results - Yahoo Finance
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - TradingView — Track All Markets
MGO One Seven LLC Buys 14,699 Shares of DexCom, Inc. $DXCM - MarketBeat
How Do Investors Really Feel About DexCom Inc? - Benzinga
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Dexcom CEO Talks G8 CGM Sensor - Medical Device and Diagnostic industry
Palmetto Grain Brokerage - Palmetto Grain Brokerage
DexCom's Q4 2025 Earnings: What to Expect - Yahoo Finance
Dexcom’s new CEO talks affordability, over-the-counter glucose sensors - Healthcare Brew
New Dexcom CEO Jake Leach talks 2026 roadmap, next-gen tech - MassDevice
DexCom (DXCM) Releases Preliminary, Unaudited Results for Q4 2025 - Insider Monkey
Dexcom’s Jake Leach on the future of continuous glucose monitoring - Modern Healthcare
Is DexCom (DXCM) Pricing Justified After Recent Multi Year Share Price Weakness - Yahoo Finance
RWC Asset Management LLP Cuts Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Bought by PKO Investment Management Joint Stock Co - MarketBeat
JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth - Yahoo Finance
GRIMES & Co WEALTH MANAGEMENT LLC Sells 17,554 Shares of DexCom, Inc. $DXCM - MarketBeat
Dexcom reports 13% revenue growth in Q4, reiterates 2025 guidance By Investing.com - Investing.com Nigeria
Barclays Downgrades DexCom (DXCM), Lowers Price Target to $71.00 - GuruFocus
Why This Medical Device Company Is the Top Stock in the S&P 500 Today - Barron's
Dexcom reports 13% rise in preliminary Q4 revenue, issues 2026 outlook - MSN
Why DexCom Is the Top Stock in the S&P 500 Today - Barron's
Barclays Downgrades DexCom to Underweight From Equal Weight, Adjusts Price Target to $71 From $80 - marketscreener.com
DexCom (DXCM) Reports Strong Preliminary Q4 and FY 2025 Revenue Growth - GuruFocus
Dexcom Updates Fiscal 2025 Revenue Guidance; Sets 2026 Outlook - marketscreener.com
Dexcom reports 13% revenue growth in Q4, reiterates 2025 guidance - Investing.com
(DXCM) DexCom Expects 2026 Total Revenue Range $5.16B$5.25B, vs. FactSet Est of $5.23B - marketscreener.com
Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch - TradingView — Track All Markets
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Business Wire
Assessing DexCom (DXCM) Valuation As Analyst Actions And Conference Spotlight Shape Sentiment - simplywall.st
DexCom (DXCM) Price Target Raised by Bernstein | DXCM Stock News - GuruFocus
Mizuho Adjusts Price Target on DexCom to $78 From $75, Maintains Outperform Rating - marketscreener.com
Bernstein Adjusts Price Target on DexCom to $86 From $84, Maintains Outperform Rating - marketscreener.com
Robeco Institutional Asset Management B.V. Lowers Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Why Dexcom (DXCM) Is Up 5.6% After Naming New CEO And Advancing AI Diabetes Platform - Sahm
How DexCom Inc. stock compares to growth peersMarket Movement Recap & Low Risk High Reward Ideas - Улправда
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
大文字化:
|
ボリューム (24 時間):